Renal side effects of Ifosfamide in patients admitted for chemotherapy

Journal of Research in Medical Sciences

Volumn 13, Issue 5, 2008, Pages 240-243

  Mashhadi, Mohammad Ali ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Ifosfamide; Nephropathy; Side effects

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; EPIRUBICIN; GRANISETRON; IFOSFAMIDE; MESNA;

ADOLESCENT; ADULT; ALBUMINURIA; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CHILDHOOD CANCER; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DRUG FEVER; DRUG HYPERSENSITIVITY; ELECTROLYTE BLOOD LEVEL; FEMALE; FOLLOW UP; GENOMICS; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HEMATURIA; HEMORRHAGIC CYSTITIS; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INFECTION; KIDNEY DISEASE; LEUKOPENIA; LIVER TOXICITY; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; PHLEBITIS; PHOSPHATE BLOOD LEVEL; PHOSPHATURIA; PHYSICAL EXAMINATION; POTASSIUM BLOOD LEVEL; PREVALENCE; PROSPECTIVE STUDY; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SODIUM BLOOD LEVEL; SOLID TUMOR; THORAX PAIN; THROMBOCYTOPENIA; UREA NITROGEN BLOOD LEVEL;

EID: 56749175983     PISSN: 17351995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Skinner R, Sharkey IM, Pearson AD, Craft AW. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 1993; 11: 173-90.
2. Skinner R. Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol 2003; 41: 190-7.
3. Stuart-Harris RC, Harper PG, Parsons CA, Kaye SB, Mooney CA, Gowing NF et al. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmacol 1983; 11: 69-72.
4. Mohrmann M, Ansorge S, Schonfeld B, Brandis M. Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells. Pediatr Nephrol 1994; 8: 458-65.
5. Skinner R, Pearson AD, Price L, Coulthard MG, Craft AW. Nephrotoxicity after ifosfamide. Arch Dis Child 1990; 65: 732-8.
6. Ashraf MS, Brady J, Breatnach F, Deasy PF, O'Meara A. Ifosfamide nephrotoxicity in paediatric cancer patients. Eur J Pediatr 1994; 153: 90-4.
7. Newbury-Ecob RA, Noble VW, Barbor PR. Ifosfamide-induced Fanconi syndrome. Lancet 1989; 1: 1328.
8. Rossi R, Godde A, Kleinebrand A, Riepenhausen M, Boos J, Ritter J et al. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol 1994; 12: 159-65.
9. Klastersky J. Side effects of ifosfamide. Oncology 2003; 65 Suppl 2: 7-10.
10. Womer RB. Ifosfamide and paediatrics: should this marriage be saved? Eur J Cancer 1996; 32A: 1100-01.
11. Van GS, Brock P, Wijndaele G, Van de CW, Kruger M, Proesmans W et al. Reversible hypophosphatemic rickets following ifosfamide treatment . Med Pediatr Oncol 1992; 20: 254-57.
12. Skinner R, Pearson AD, English MW, Price L, Wyllie RA, Coulthard MG et al. Risk factors for ifosfamide nephrotoxicity in children. Lancet 1996; 348: 578-80.
13. Skinner R, Cotterill SJ, Stevens MC. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group. Br J Cancer 2000; 82: 1636-45.
14. Kamen BA, Frenkel E, Colvin OM. Ifosfamide: should the honeymoon be over? J Clin Oncol 1995; 13: 307-9.